Hybrid Nanostructured Oligonucleotide Platforms for Biomedical Applications (Nano-OligoMed)

Nanotechnology has received widespread attention in the last several decades due to the technological breakthroughsit has enabled across sectors from electronics to medicine. Towards the great challenges that nanotechnology arise,Nano-OligoMed has the ambition to establish and support a network of international collaboration, enabling acollaborative scientific team to effectively use a diversity of approaches and strategies to generate and test hybridnanomaterials for the efficient and safe systemic delivery of oligonucleotide-based therapeutic agents. To this end, wehave set-up a joint multidisciplinary scientific collaborative programme that through exchange, international mobility,and strongly collaborative transfer of knowledge and training activities between 4 European and 3 extra-Europeancountries, will bring together leading experts under the field of “nanomaterials in biomedicine”. The scientific aim ofNano-OligoMed is the creation of degradable hybrid structures that combine the rigid, inert silica with the delicateprogrammable oligonucleotides or artificial oligonucleotide-mimics. The possibility to develop novel oligonucleotide-based materials will enable a) the degradation of the drug carrier at the presence of a specific input as a function of theintrinsic bio-responsive feature of oligonucleotides, b) the activation of a therapeutic function as a result of the bio-molecular interaction between the oligonucleotide-based material and the molecular target (i.e. miRNAs) and c) thedelivery of the chemical payload (DNA and/or artificial mimics, even in combination with cancer drugs) upon cellinternalization. The international academic networking, the broadening of the research skills, the educational activities,will provide to young (PhD students) and senior scientists, specific competences in the field of materials sciences,nanotechnology, molecular biology and molecular medicine.Associated with document Ref. Ares(2017)5329121 - 31/10/2017